Retraction note: Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphoma

Shoubing Zhou; Xiu Zhang; Cailian Wang

doi:10.18632/oncotarget.14897

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Retraction:

Retraction note: Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphoma

Shoubing Zhou, Xiu Zhang and Cailian Wang _

PDF | How to cite

Oncotarget. 2017; 8:8992-8992. https://doi.org/10.18632/oncotarget.14897

Metrics: PDF 3088 views | ?

Retraction: Due to the authors’ negligence during the preparation of this manuscript for submission, it contains a plethora of data errors. Authors sincerely apologize for their mistakes and wish to retract their manuscript.

Original article: Oncotarget. 2017; 8(3):4760-4772. DOI: 10.18632/oncotarget.13587

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14897

Publication Alerts

Post-Publication Promotion

Publication Discount

Retraction:

Retraction note: Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphoma